immunogen
hlaa
cytotox
lymphocyt
ctl
peptid
sever
acut
respiratori
syndrom
coronaviru
sarscov
nuclear
capsid
n
spike
protein
determin
test
protein
abil
elicit
specif
cellular
immun
respons
immun
transgen
mice
vitro
vaccin
posit
human
peripher
blood
mononuclearcyt
pbmc
first
screen
sar
n
amino
acid
sequenc
allelespecif
motif
match
human
mhci
molecul
hla
peptid
bind
predict
http
thrcitnihgovmolbiohlabind
ten
potenti
nand
sspecif
peptid
synthes
high
affin
peptid
valid
stabil
assay
immunogen
assay
reveal
peptid
first
identifi
hlaa
ctl
epitop
sarscov
n
protein
addit
previou
report
identifi
three
hlaa
ctl
epitop
protein
found
two
novel
peptid
sspecif
ctl
epitop
moreov
identifi
ctl
epitop
could
induc
recal
respons
ifnc
stimul
blood
tcell
reveal
signific
differ
normal
healthi
donor
sarsrecov
patient
pbmc
vitro
vaccin
cognat
antigen
result
would
provid
new
insight
develop
therapeut
vaccin
sar
hlaa
tcell
epitop
sever
acut
respiratori
syndrom
sar
coronaviru
nucleocapsid
spike
protein
sever
acut
respiratori
syndrom
sar
caus
novel
coronavirussarsassoci
coronaviru
sarscov
sarscov
envelop
positivestrand
rna
viru
four
structur
gene
sar
gene
encod
spike
glycoprotein
play
role
cellcel
fusion
small
membran
protein
e
integr
membran
glycoprotein
n
gene
encod
nucleocapsid
rnabind
protein
may
associ
viral
protein
presum
sarscov
infect
cell
protein
bind
cell
surfac
receptorangiotensinconvert
enzym
initi
attach
viral
e
protein
fuse
plasma
membran
host
cell
cascad
intracellular
event
follow
includ
interact
n
protein
henc
four
structur
protein
major
target
develop
antisar
drug
vaccin
date
mani
effort
made
find
vaccin
block
sarscov
infect
elimin
viral
load
infecti
bronchiti
viru
ibv
prototyp
coronavirida
famili
caus
highli
contagi
respiratori
diseas
chicken
ibvspecif
ctl
critic
play
role
elimin
viru
particl
acut
infect
subsequ
control
infect
chicken
therefor
ctl
may
determin
role
immun
control
viral
pathogenesi
project
gener
sarscov
ctl
respons
chose
analyz
two
structur
geness
n
defin
hlaa
ctl
epitop
futur
vaccin
human
ctl
specif
peptid
present
context
major
histocompat
complex
mhc
molecul
prior
present
peptid
gener
cytosol
limit
proteolyt
fragment
avail
antigen
transloc
endoplasm
reticulum
specif
sampl
mhc
molecul
export
cell
surfac
await
ctl
scrutini
subunit
vaccin
contain
small
synthet
peptid
correspond
minim
cytotox
lymphocyt
ctl
epitop
shown
highli
effect
induct
strong
protect
ctlmediat
immun
infecti
viru
tumor
growth
murin
model
henc
studi
map
hlaa
ctl
epitop
sarscov
n
protein
use
onlin
databas
analysi
predict
hla
bind
peptid
sarscov
n
protein
valid
bind
assay
result
identifi
three
nand
two
sspecif
hlaa
peptid
moreov
identifi
ctl
epitop
could
induc
recal
respons
ifnc
stimul
blood
tcell
reveal
signific
differ
normal
healthi
donor
sarsrecov
patient
pbmc
vitro
vaccin
cognat
antigen
peptid
synthesi
determin
potenti
vaccin
candid
ten
potenti
acid
peptid
sarscov
n
protein
synthes
addit
peptid
ymdgtmsqv
tyrosinas
peptid
eadptghsi
test
posit
neg
control
respect
peptid
synthes
solidphas
strategi
autom
peptid
synthes
abim
am
use
fmoc
chemistri
peptid
analyz
reversephas
highperform
liquid
chromatographi
hplc
dissolv
dimethyl
sulfoxid
dmso
mgml
liquat
store
stabil
assay
stabil
surfac
synthet
peptid
determin
whether
synthet
peptid
could
bind
hlaa
molecul
peptideinduc
hlaa
upregul
examin
accord
protocol
describ
previous
measur
rel
amount
complex
form
cell
incub
lg
n
protein
peptid
h
hbss
supplement
fb
lgml
human
b
sigma
lgml
brefeldin
variou
titrat
peptid
bind
assay
test
lg
peptid
approxim
concentr
assay
data
shown
cell
wash
incub
addit
h
allow
remain
peptidefre
mhc
molecul
denatur
follow
indirect
immunofluoresc
stain
express
ab
goat
antimous
igg
f
ab
fitc
jackson
immunoresearch
west
grove
pa
fix
paraformaldehyd
analyz
flow
cytometri
result
calcul
percentag
express
use
formula
fluoresc
intens
experiment
peptid
bind
mock
peptid
bind
product
recombin
n
protein
recombin
n
protein
express
prseta
vector
invitrogen
carlsbad
ca
usa
escherichia
coli
system
gold
stratagen
cedar
creek
tx
usa
dna
recombin
technolog
purifi
ninta
resin
report
liu
et
al
anim
transgen
mice
purchas
import
jackson
laboratori
maintain
institut
specif
pathogenfre
condit
transgen
mice
background
express
mhci
molecul
human
describ
previous
transgen
mice
receiv
sspecif
peptid
lg
n
protein
lg
lg
cpg
oligodeoxynucleotid
cpg
odn
via
intramuscular
inject
three
time
one
week
interv
one
week
last
immun
map
ctl
epitop
n
protein
analyz
antigenspecif
interferonc
ifnc
doubleposit
cell
transgen
mice
flow
cytometri
intracytoplasm
cytokin
stain
flow
cytometri
analysi
splenocyt
peptid
vaccin
transgen
mice
control
incub
h
lg
stimul
n
synthet
peptid
detect
n
peptidespecif
tcell
precursor
golgistop
pharmingen
san
diego
ca
ad
well
h
cell
harvest
cell
wash
twice
facscan
buffer
stain
fluorescein
isothiocyan
fitc
conjug
rat
antimous
monoclon
antibodi
pharmingen
cell
subject
intracellular
cytokin
stain
use
cytofixcytoperm
kit
accord
manufactur
instruct
pharmingen
phycoerythrinconjug
rat
antimous
ifnc
monoclon
antibodi
purchas
pharmingen
fac
analysi
perform
bectondickinson
facscan
cellquest
softwar
bectondickinson
immunocytometri
system
mountain
view
ca
hlaa
type
blood
sampl
collect
acid
citrat
dextros
tube
transport
within
h
immunohematolog
refer
laboratori
mackay
memori
hospit
taipei
taiwan
sampl
test
hlaa
b
c
serolog
standard
microlymphocytotox
techniqu
use
terasaki
chines
hlaabc
tray
lot
vitro
vaccin
ifnc
assay
sampl
obtain
inform
consent
triservic
gener
hospit
mackay
memori
hospit
taipei
taiwan
studi
approv
institut
human
investig
review
committe
human
pbmc
isol
respect
normal
full
recoveri
patient
sever
sarsinfect
hlaa
type
separ
ficollhypaqu
densiti
gradient
resuspend
tcell
medium
five
recoveri
patient
includ
one
laboratori
worker
four
hospit
nurs
contract
sarscov
epidem
period
afflict
sar
diseas
hospit
full
recoveri
identifi
viru
rna
respiratori
secret
antibodi
sarscov
detect
sarsspecif
igg
captur
elisa
endpoint
dilut
ab
titer
ab
titer
observ
recov
patient
ab
sarscov
detect
healthi
donor
patient
blood
harvest
one
year
postinfect
isol
peripher
blood
mononuclear
cell
incub
plastic
dish
h
nonadher
lymphocyt
aspir
adher
fraction
cultur
medium
contain
poll
human
ab
serum
recombin
granulocytemacrophag
colonystimul
factor
gmcsf
iuml
recombin
human
interleukin
iuml
r
system
minneapoli
minn
one
hundr
microgram
recombin
n
protein
combin
multipl
peptid
incub
adher
cell
recombin
human
interleukin
iuml
recombin
human
interleukin
iuml
recombin
human
interleukin
ngml
recombin
human
tumor
necrosi
factoralpha
tnfa
ngml
ad
everi
second
day
antigenvaccin
adher
cell
three
day
initi
addit
antigen
adher
cell
autolog
blood
lymphocyt
nonadher
cell
well
coincub
adher
cell
second
day
recombin
human
interleukin
iuml
ad
cultur
fed
medium
contain
penicillin
streptomycin
day
cultur
tcell
purifi
label
blood
lymphocyt
magnet
microbead
coat
antibodi
accord
manufactur
recommend
miltenyi
biotech
gmbh
separ
automac
devic
miltenyi
biotech
gmbh
use
seri
procedur
isol
tcell
stimul
indic
peptid
next
day
supernat
collect
analyz
ifnc
polyclon
ab
elisa
kit
quantikin
r
system
seri
concentr
standard
protein
pgml
paral
measur
refer
accordingli
concentr
ifnc
test
calcul
defin
hlaa
epitop
n
protein
sarscov
bind
assay
screen
amino
acid
sequenc
n
protein
sarscov
use
hla
peptid
bind
predict
offer
nation
institut
health
nih
http
thrcitnihgovmolbiohlabind
determin
potenti
ctl
epitop
estim
dissoci
halflif
mhc
class
molecul
ten
potenti
nand
sspecif
peptid
along
posit
neg
control
peptid
synthes
supplement
tabl
subject
bind
assay
valid
bind
affin
tyrosinederiv
peptid
ymdgtmsqv
serv
posit
control
peptid
eadptghsi
serv
neg
control
onlin
databas
analysi
bind
affin
assay
reveal
three
n
peptid
fig
two
peptid
fig
exhibit
strong
bind
molecul
transgen
mice
wide
use
preclin
diseas
model
provid
inform
relev
clinic
trial
design
transgen
mice
background
express
class
mhc
molecul
human
describ
previous
use
mice
map
ctl
epitop
vaccin
transgen
mice
lg
recombin
n
protein
three
time
one
week
interv
one
week
last
vaccin
splenocyt
harvest
stimul
bind
peptid
nonbind
peptid
separ
ctl
assay
ifnc
doubl
stain
flow
cytometri
shown
fig
peptid
stimul
result
ifnc
tcell
detect
per
splenocyt
deriv
sarscov
n
protein
vaccin
approxim
increas
peptid
stimul
compar
non
bind
peptid
respect
fig
ifnc
product
cell
fig
suggest
natur
killer
cell
may
involv
worth
investig
sum
peptid
could
act
stimul
induc
sarscov
nspecif
ctl
respons
identif
sarscov
n
ctl
epitop
transgen
mice
vaccin
bind
peptid
plu
cpg
odn
immun
experi
conduct
three
bind
peptid
n
protein
two
peptid
well
bind
fig
b
test
capac
induc
peptidespecif
ctl
immun
vivo
cpg
phosphorothio
oligodeoxynucleotid
cpg
odn
use
adjuv
transgen
mice
receiv
peptid
cpg
odn
via
intramuscular
inject
three
time
one
week
interv
one
week
third
immun
measur
peptidespecif
ctl
activ
analyz
antigenspecif
ifnc
doubleposit
cell
transgen
mice
flow
cytometri
shown
fig
b
ctl
activ
result
vaccin
peptid
significantli
increas
respect
compar
bind
cutoff
signific
immun
respons
studi
chosen
fourfold
differ
stimul
peptid
irrelev
peptideinduc
ctl
likewis
determin
ctl
epitop
ctl
activ
result
vaccin
peptid
increas
respect
supplement
fig
indic
peptid
immunogen
ctl
epitop
sarscov
protein
recent
sever
group
measur
vaccin
efficaci
vitro
vaccin
pbmc
cancer
patient
peptid
tumor
cell
solubl
protein
viru
like
particl
recombin
adenovirus
show
vitro
vaccin
agent
could
trigger
human
ctl
tumor
antigen
moreov
recent
report
demonstr
vitro
vaccin
healthi
donor
human
papillomaviru
type
protein
gener
ctl
clone
indic
ctl
clone
gener
vitro
vaccin
pbmc
either
patient
normal
healthi
avoid
radioact
risk
use
elisa
measur
ifnc
releas
purifi
tcell
ctl
assay
instead
chromium
releas
assay
elispot
assay
perform
elispot
elisa
ifnc
product
purifi
tcell
parallel
result
two
assay
coher
data
shown
therefor
studi
examin
ctl
activ
ifnc
releas
purifi
tcell
elisa
kit
lymphocyt
obtain
five
hlaa
donor
fulli
recov
sarscov
infect
five
hlaa
healthi
donor
histori
sarscov
infect
adher
nonadher
cell
isol
divid
human
blood
separ
ficollhypaqu
densiti
gradient
describ
materi
method
recombin
n
protein
combin
peptid
protein
introduc
isol
adher
cell
vaccin
adher
cell
cocultur
autolog
lymphocyt
nonadher
cell
two
week
coincub
tcell
isol
purif
tcell
analyz
flow
cytometri
result
show
tcell
nk
cell
exist
data
shown
isol
tcell
stimul
peptid
ifnc
product
assay
elisa
shown
fig
stimul
peptid
produc
high
amount
ifnc
normal
healthi
fulli
recov
sarscov
infect
patient
low
respons
irrelev
peptid
posit
control
tcell
respons
influenza
viru
matrix
peptid
stimul
signific
tcell
respons
nonhlaa
healthi
donor
sarscov
infect
patient
data
shown
data
deriv
averag
five
individu
group
indic
human
antigen
present
cell
process
n
protein
therefor
present
mhc
molecul
complex
n
peptid
tcell
therefor
peptid
endogen
ctl
epitop
n
protein
likewis
vitro
vaccin
data
show
peptid
sspecif
ctl
epitop
fig
furthermor
look
recal
respons
ctl
peptid
ifnc
product
blood
tcell
respons
ctl
epitop
stimul
reveal
signific
differ
normal
healthi
donor
sarsrecoveri
patient
pbmc
vitro
vaccin
cognat
antigen
indic
two
ctl
peptid
recoveri
patient
induc
higher
immun
respons
normal
healthi
fig
b
howev
ctl
epitop
stimul
show
signific
differ
normal
donor
sarsrecov
patient
indic
norecal
respons
three
peptid
exist
blood
lymphocyt
fulli
convalesc
sarscov
infect
patient
studi
first
identifi
n
peptid
hlaa
ctl
epitop
sarscov
n
protein
two
novel
ctl
epitop
addit
three
epitop
alreadi
known
immun
transgen
mice
vitro
vaccin
hlaa
posit
human
pbmc
measur
immunogen
sarscov
infect
n
protein
report
highli
immunogen
larg
quantiti
found
serolog
assay
earli
stage
sarscov
infect
patient
similarli
n
antigen
also
found
highli
immunogen
elk
cov
ibv
howev
report
concern
nspecif
ctl
epitop
elicit
cellular
immun
respons
human
sever
publish
paper
sarscov
n
protein
vaccin
develop
experiment
anim
exampl
n
vaccin
effici
gener
nspecif
humor
tcellmedi
immun
respons
vaccin
mice
monkey
studi
first
identifi
three
nspecif
hlaa
ctl
epitop
stimul
ifnc
releas
tcell
via
vitro
vaccin
human
blood
lymphocyt
healthi
donor
sarscov
fulli
recov
patient
therefor
three
tcell
epitop
peptid
good
candid
least
partial
constitut
antisarscov
vaccin
sarscov
acid
type
membran
glycoprotein
promin
protein
present
viral
membran
present
typic
spike
structur
found
coronavirus
glycoprotein
domain
structur
deduc
sequenc
analysi
glycoprotein
consist
leader
amino
acid
ectodomain
repres
amino
acid
membran
span
domain
amino
acid
short
intracellular
tail
amino
acid
previous
three
sspecif
hlaa
ctl
epitop
report
studi
found
two
novel
sspecif
hlaa
ctl
epitop
wang
et
al
use
syfpeithi
epitopepredict
predict
sspecif
hlaa
bind
affin
epitop
identifi
peptid
sspecif
hlaa
ctl
epitop
studi
use
nih
databas
predict
potenti
hlaa
bind
peptid
identif
ctl
epitop
protein
valid
bind
assay
immunogen
measur
transgen
mice
vitro
vaccin
human
pbmc
identif
ctl
epitop
protein
unlik
n
protein
avail
entir
protein
vaccin
studi
induct
ctl
activ
via
vitro
vaccin
human
blood
lymphocyt
found
studi
similar
stimul
effect
identifi
wang
et
al
fig
henc
regard
two
novel
sspecif
hlaa
ctl
epitop
recent
angiotensinconvert
enzym
found
function
receptor
sarscov
protein
subsequ
receptorbind
domain
locat
amino
acid
residu
therefor
includ
result
present
studi
five
known
sspecif
ctl
epitop
seem
involv
receptor
bind
host
henc
bind
domain
amino
acid
protein
receptor
strong
ctl
activ
hlaa
human
hand
bcell
epitop
spike
protein
found
among
epitop
cover
amino
acid
protein
report
bcell
antigen
epitop
recognit
monoclon
antibodi
recent
report
also
reveal
amino
acid
immunodomin
site
human
humor
immun
system
recogn
interact
short
peptid
fragment
locat
loop
region
predict
n
helic
spike
protein
close
proxim
glycosyl
site
identifi
glutamin
suggest
fragment
surfac
spike
protein
data
combin
result
reveal
tcell
epitop
identifi
studi
may
elicit
strong
humor
cellular
immun
may
valuabl
candid
vaccin
develop
studi
tcell
normal
healthi
donor
could
induc
tcell
respons
speptid
stimul
whose
blood
lymphocyt
vitro
vaccin
cognat
antigen
fig
b
indic
either
n
antigen
may
stimul
normal
human
blood
tcell
becom
effect
ctl
vitro
recent
studi
similarli
report
heatinactiv
sarscov
elicit
ctl
respons
human
papillomaviru
type
ctl
clone
gener
vitro
vaccin
normal
healthi
blood
lymphocyt
would
suggest
matur
dendrit
cell
capabl
activ
sarscov
nand
sspecif
ctl
precursor
vitro
studi
n
peptid
well
peptid
identifi
nand
sspecif
hlaa
ctl
epitop
respect
among
ctl
peptid
could
induc
recal
respons
ctl
epitop
fig
sinc
ifnc
product
ctl
epitop
stimul
reveal
signific
differ
normal
healthi
donor
sarsrecoveri
patient
pbmc
vitro
vaccin
cognat
antigen
indic
two
ctl
peptid
trigger
recal
respons
fig
howev
ifnc
secret
ctl
epitop
stimul
show
signific
differ
normal
donor
sarsrecov
patient
indic
norecal
respons
three
peptid
exist
blood
lymphocyt
fulli
convalesc
sarscov
infect
patient
previou
report
identifi
two
sspecif
hlaa
ctl
epitop
tcell
specif
immun
respons
two
epitop
observ
hlaa
sarscov
infect
patient
healthi
donor
test
two
peptid
along
find
ctl
epitop
result
show
elicit
differ
immun
respons
healthi
donor
recov
patient
fig
differ
result
assay
assay
time
studi
tcell
immun
analyz
one
month
sarscov
infect
recov
patient
studi
test
least
one
year
viru
infect
would
suggest
memori
cell
exist
blood
sarscov
recov
patient
may
longliv
confirm
continu
report
elicit
agspecif
recal
respons
analyz
ctl
respons
pbmc
inactiv
sarscov
sarsrecov
patient
one
year
recoveri
sum
memori
tcell
seem
longliv
henc
two
peptid
becom
valuabl
candid
futur
vaccin
diagnosi
marker
sar
prevent
infect
due
declin
sar
epidem
acut
sar
patient
avail
illustr
balanc
pathogenesi
immun
reaction
sar
result
would
provid
new
insight
develop
immun
respons
sarscov
infect
approach
therapeut
vaccin
sar
